Optimized Oral Formulation Demonstrates Favorable Oral Bioavailability Together with Robust Brain and Liver Distribution Following Oral Administration

MIAMI, FL / ACCESS Newswire / July 10, 2026 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company, today announced positive results from preclinical studies evaluating optimized oral formulations of MIRA-55, the Company's oral drug candidate being developed as a non-opioid therapy for chronic inflammatory pain.

Following evaluation of multiple oral formulations, the Company selected a lead formulation demonstrating favorable oral bioavailability together with sustained systemic exposure and reproducible distribution into both brain and liver tissue following oral administration. Collectively, these findings support the continued development of MIRA-55 as an orally administered therapy for chronic inflammatory pain.

The objective of the study was to optimize the oral formulation of MIRA-55 by comparing multiple formulations in a preclinical pharmacokinetic study. An intravenous reference arm was included to characterize absolute oral bioavailability and support selection of the lead formulation based on its overall pharmacokinetic profile.

The selected formulation demonstrated reproducible distribution into both brain and liver tissue following oral administration. Brain exposure may support modulation of central pain-processing pathways, while peripheral distribution may contribute to the anti-inflammatory activity previously observed in MIRA's preclinical efficacy studies. Together, these findings demonstrate that the optimized formulation successfully delivers MIRA-55 to pharmacologically relevant tissues associated with both central and peripheral mechanisms of chronic inflammatory pain.

Today's pharmacokinetic findings build upon MIRA's previously reported preclinical studies demonstrating that oral MIRA-55 normalized pain and reduced inflammation in a validated inflammatory pain model, outperforming injected morphine, while also exhibiting a differentiated pharmacological profile relative to THC. In separate mechanistic and behavioral studies, MIRA-55 demonstrated anxiolytic activity, did not produce the characteristic central nervous system effects associated with THC, and was shown to interact with the cannabinoid system through a mechanism distinct from THC. Collectively, these efficacy, behavioral, mechanistic, and pharmacokinetic findings continue to strengthen the overall development package supporting MIRA-55 as a differentiated oral therapeutic candidate for chronic inflammatory pain.

The Company plans to continue evaluating the relationship between tissue exposure, pharmacodynamic activity, and therapeutic efficacy as MIRA-55 advances through additional preclinical development.